Hernández Martínez Adrian, Pereira Delgado Ernesto, Silva Silva Guillermo, Castellanos Mateos Luis, Lorente Pascual José, Lainez Villa Julian, García Vicente Paula, Almeida-González Carmen-Victoria
Ophthalmology Department, Nuestra Señora de Valme University Hospital, Seville, Spain.
Oftalvist Sevilla, Sevilla, Spain.
Eur J Ophthalmol. 2020 Sep;30(5):1091-1098. doi: 10.1177/1120672119848257. Epub 2019 May 16.
To compare the results of early versus late switch to the dexamethasone intravitreal implant Ozurdex in patients with diabetic macular edema who had a poor response to vascular endothelial growth factor inhibitors.
Retrospective and single-center study conducted, in a real setting, on consecutive diabetic macular edema patients who were switch to an intravitreal dexamethasone implant after a poor response to anti-vascular endothelial growth factor treatment. Study sample was divided into two groups: (1) early-switch group, included those eyes who received three anti-vascular endothelial growth factor injections before switch and (2) late-switch group, included those eyes that received six or more anti-vascular endothelial growth factor injections before switch. The primary end-point was the difference in mean change in best-corrected visual acuity and in central subfoveal thickness.
A total of 69 (31 early-switch group and 38 late-switch group) eyes were included. In the early-switch group, median (25-75 quartile range) best-corrected visual acuity significantly increase from 0.2 (0.2-0.5) at baseline to 0.4 (0.3 -0.7) at month 24 (p = 0.0043). Whereas, in the late-switch group, best-corrected visual acuity did not increase (p = 0.8602). Central subfoveal thickness was significantly reduced in both early- and late-switch groups, p = 0.0002 and 0.0038, respectively. The proportion of eyes obtaining a central subfoveal thickness reduction ⩾ 10% was significantly greater in the early-switch group than in the late-switch group (71.0% vs 47.4%, respectively, p = 0.0498). Three (9.7%) and 10 (26.3%) eyes have developed ocular hypertension during the study in the early- and late-switch groups, respectively, p = 0.0816.
Early switch to Ozurdex in patients who did not adequately respond to anti-vascular endothelial growth factor therapy provided better functional and anatomical outcomes.
比较糖尿病性黄斑水肿患者对血管内皮生长因子抑制剂反应不佳时,早期与晚期改用玻璃体内注射地塞米松植入剂Ozurdex的效果。
在实际环境中进行一项回顾性单中心研究,研究对象为连续的糖尿病性黄斑水肿患者,这些患者在对抗血管内皮生长因子治疗反应不佳后改用玻璃体内地塞米松植入剂。研究样本分为两组:(1)早期改用组,包括那些在改用前接受过3次抗血管内皮生长因子注射的眼睛;(2)晚期改用组,包括那些在改用前接受过6次或更多次抗血管内皮生长因子注射的眼睛。主要终点是最佳矫正视力和中心凹下厚度的平均变化差异。
共纳入69只眼(早期改用组31只眼,晚期改用组38只眼)。在早期改用组中,最佳矫正视力中位数(25 - 75四分位数范围)从基线时的0.2(0.2 - 0.5)显著提高到第24个月时的0.4(0.3 - 0.7)(p = 0.0043)。而在晚期改用组中,最佳矫正视力没有提高(p = 0.8602)。早期和晚期改用组的中心凹下厚度均显著降低,p值分别为0.0002和0.0038。早期改用组中心凹下厚度降低≥10%的眼睛比例显著高于晚期改用组(分别为71.0%和47.4%,p = 0.0498)。在研究期间,早期和晚期改用组分别有3只眼(9.7%)和10只眼(26.3%)发生了高眼压,p = 0.0816。
对于对抗血管内皮生长因子治疗反应不充分的患者,早期改用Ozurdex可提供更好的功能和解剖学结果。